Bridget Martell, MD

Venture Partner


Dr. Martell is a high impact, results-oriented scientific biotech executive with breadth and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research.

Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.